IKZF1 and acute lymphoblastic leukemia: These data not only indicate the effect of CK2 inhibitor to increase Ikaros function as a transcriptional regulator, but also suggest that Ikaros-induced changes in IL7R/SH2B3 expression are at least partially responsible for the success of CK2 inhibitors in ALL therapy.